Biomarker and Target Identification in GEP-NET: From in Silico Prediction to Validation on Patient Tissues Abstract #1483

Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a heterogeneous group of tumors. Somatostatin agonist treatment has a key role in the management of GEP-NET. However, the prognosis of these tumors varies between individuals. There is, therefore, a need to identify novel prognostic and predictive biomarkers of therapeutic efficacy, as well as to propose novel therapeutic strategies.
Aim(s): To optimize this approach, we adopted a strategy that uses a curated biological knowledge source coupled with a proprietary data mining methodology (iFit) followed by wet lab experiments. In this poster, we highlight some of the results of the experimental validation.
Materials and methods: We selected 10 miRs and 42 mRNAs coding for G protein coupled receptors (GPCRs) that were identified with iFiT, for evaluation in tumor functioning or not from 40 metastatic or not patients (20 pancreatic NET and 20 ileal NET). The nanostring® platform was used for miRNAs and mRNAs analysis and immunohistochemistry was carried out for 11 GPCRs.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Biomarkers
Presenting Author: Pascale Plas
Keywords: GPCR, miR

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1467 iFiT: An Integrative Bioinformatics Platform for Biomarker and Target Discovery. A Case Study in Neuroendocrine Tumors
Introduction: iFiT (Ipsen Focused-on-new bIological enTities and biomarkers) is a Bioinformatics platform integrating systems biology functionalities together with semantic & logic-based artificial intelligence within a high-scale computing environment.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Biomarkers
Presenting Author: PhD Sebastien Tourlet
Keywords: Targets iFiT
#3058 Diagnosis and Assessment of Effectiveness of Surgical Resection of Small Bowel Neuroendocrine Tumours: The Roles of Circulating MicroRNAs
Introduction: MicroRNAs (miRNA) are small noncoding RNA molecules implicated in the pathophysiology of myriad neoplasms. Clinically useful biomarkers are needed in SB NET to ascertain disease aggressiveness, select treatment strategy, detect early recurrence and monitor response.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: Dr Ashley Clift
#2824 Patient and Nurse Satisfaction with the New Lanreotide Autogel Pre-Filled Syringe in Neuroendocrine Tumors (NET): A Prospective Study (SONATE)
Introduction: A new syringe (NS) for the delivery of lanreotide autogel was approved in Oct 2018 in France. The NS includes updated features (larger flanges, more robust plunger) intended to ease the injection.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Dr. Olivier Mir
Authors: Walter T, Eskenazi M, Rama N, Gueguen D, ...
#2962 90Y- and/or 177Lu-DOTATOC Re-Challenge in Patients with Progressive Neuroendocrine Tumors
Introduction: Most patients treated with PRRT will eventually progress. Previous studies indicated that repeated PRRT is feasible and promising.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr. med. Susanne Aberle
Authors: Aberle S, Benz M, Grokovski R, Christ E, ...
#3057 Epidemiological Features of Patients with NeuroEndocrine Neoplasms (NENs): Preliminary Results of an Observational Study by the Hellenic Society of Medical Oncology (HeSMO)
Introduction: NENs are rare tumors and can grow in almost all tissues. Regardless histological, molecular and imaging characteristics that are indicative of the primary origin, a significant percentage remain of unknown primary.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD, MSc, PhD Nikolaos Tsoukalas